Today's Stock Market Highlights: L&T, Dr Reddy’s, TCS, and More
Today's Stock Market Highlights: L&T, Dr Reddy’s, TCS, and More
Stay informed with the latest updates on top-performing stocks today, including L&T's impressive growth, Dr Reddy's Labs' financial results, and TCS's strategic partnership with Aviva. Explore market insights on PB Fintech, SRF, Voltas, and Astral to make informed investment decisions.
(1) L&T: Recorded 15% yoy growth in consolidated net profit at ₹2,947 crore for the December quarter. Consolidated revenue from operations grew 19% yoy to ₹55,128 crore.
(2) Dr Reddy’s Laboratories: Registered 10.6% yoy growth in consolidated net profit at ₹1,378.9 crore for the December quarter, despite higher tax cost. Revenue from operations rose 6.6% to ₹7,215 crore from a year ago.
(3) SRF: Quarterly numbers were weaker than estimated, owing to the chemicals business. Ebitda margin was 18.5% from 24% last year. Ebitda was down 32.1% and net profit down 50%.
(4) Voltas: Posted a net loss of ₹27.6 crore for the December quarter, narrowing from a loss of ₹110.5 crore a year ago despite a healthy topline, thanks to increased input costs. Consolidated revenue from operations increased 31% yoy to ₹2,625.7 crore.
(5) TCS: Announced a 15-year expansion of its partnership with Aviva, the British insurance, wealth and retirement provider, to transform its business and enhance customer experience.
(6) PB Fintech: The parent firm of Policybazaar posted a net profit of ₹37 crore for the December quarter, against a net loss of ₹87 crore a year ago. Revenue from operations jumped 43% you to ₹871 crore.
(7) Astral: Revenue came in at ₹1,371 crore, below estimates of ₹1,436 crore, while Ebitda was up 12.8% to ₹204.6 crore, also below estimates. Revenue from the plumbing segment rose 7.1% from last year, revenue from paints and adhesives increased by 10.7%. Both the PVC and CPVC divisions posted inventory losses in the quarter, while pipe sales volume rose 15% to 52.7 kt.
Conclusion
In today's stock market, L&T stands out with robust growth in net profit, while Dr Reddy's Laboratories and PB Fintech also exhibit positive trends. SRF faces challenges in its chemicals business, Voltas narrows its losses, and TCS expands its strategic partnership with Aviva. Astral experiences mixed results with revenue below estimates and inventory losses in PVC and CPVC divisions.
Q1: How did L&T perform in the December quarter?
Ans :- L&T recorded an impressive 15% YoY growth in consolidated net profit, reaching ₹2,947 crore, and a 19% growth in consolidated revenue from operations, amounting to ₹55,128 crore.
Q2: What were the key financials for Dr Reddy’s Laboratories?
Ans:- Dr Reddy’s Laboratories achieved a 10.6% YoY growth in consolidated net profit, reaching ₹1,378.9 crore, and a 6.6% increase in revenue from operations, totaling ₹7,215 crore.
Q3: What challenges did SRF face in its quarterly numbers?
Ans :- SRF experienced weaker-than-estimated quarterly numbers, primarily due to challenges in its chemicals business. Ebitda margin decreased to 18.5%, Ebitda was down by 32.1%, and net profit decreased by 50%.
Q4: How did Voltas perform in the December quarter?
Ans :- Voltas posted a net loss of ₹27.6 crore, narrowing from ₹110.5 crore a year ago. However, it achieved a healthy topline with a 31% YoY increase in consolidated revenue from operations, reaching ₹2,625.7 crore.
Q5: What strategic move did TCS announce today?
Ans :- TCS announced a 15-year expansion of its partnership with Aviva, the British insurance, wealth, and retirement provider. This move aims to transform Aviva's business and enhance customer experience.
Q6: What were the financial highlights for PB Fintech (Policybazaar's parent firm)?
Ans:- PB Fintech, the parent firm of Policybazaar, posted a net profit of ₹37 crore for the December quarter, a significant improvement from a net loss of ₹87 crore a year ago. Revenue from operations also saw a substantial 43% YoY jump, reaching ₹871 crore.
✅नवीनतम जानकारी के लिए, आपको वित्तीय न्यूज और वित्त सलाहकारों के साथ संपर्क करना चाहिए।
(1) L&T: Recorded 15% yoy growth in consolidated net profit at ₹2,947 crore for the December quarter. Consolidated revenue from operations grew 19% yoy to ₹55,128 crore.
(2) Dr Reddy’s Laboratories: Registered 10.6% yoy growth in consolidated net profit at ₹1,378.9 crore for the December quarter, despite higher tax cost. Revenue from operations rose 6.6% to ₹7,215 crore from a year ago.
(3) SRF: Quarterly numbers were weaker than estimated, owing to the chemicals business. Ebitda margin was 18.5% from 24% last year. Ebitda was down 32.1% and net profit down 50%.
(4) Voltas: Posted a net loss of ₹27.6 crore for the December quarter, narrowing from a loss of ₹110.5 crore a year ago despite a healthy topline, thanks to increased input costs. Consolidated revenue from operations increased 31% yoy to ₹2,625.7 crore.
(5) TCS: Announced a 15-year expansion of its partnership with Aviva, the British insurance, wealth and retirement provider, to transform its business and enhance customer experience.
(6) PB Fintech: The parent firm of Policybazaar posted a net profit of ₹37 crore for the December quarter, against a net loss of ₹87 crore a year ago. Revenue from operations jumped 43% you to ₹871 crore.
(7) Astral: Revenue came in at ₹1,371 crore, below estimates of ₹1,436 crore, while Ebitda was up 12.8% to ₹204.6 crore, also below estimates. Revenue from the plumbing segment rose 7.1% from last year, revenue from paints and adhesives increased by 10.7%. Both the PVC and CPVC divisions posted inventory losses in the quarter, while pipe sales volume rose 15% to 52.7 kt.
Conclusion
In today's stock market, L&T stands out with robust growth in net profit, while Dr Reddy's Laboratories and PB Fintech also exhibit positive trends. SRF faces challenges in its chemicals business, Voltas narrows its losses, and TCS expands its strategic partnership with Aviva. Astral experiences mixed results with revenue below estimates and inventory losses in PVC and CPVC divisions.
Frequently asked questions
Q1: How did L&T perform in the December quarter?
Ans :- L&T recorded an impressive 15% YoY growth in consolidated net profit, reaching ₹2,947 crore, and a 19% growth in consolidated revenue from operations, amounting to ₹55,128 crore.
Q2: What were the key financials for Dr Reddy’s Laboratories?
Ans:- Dr Reddy’s Laboratories achieved a 10.6% YoY growth in consolidated net profit, reaching ₹1,378.9 crore, and a 6.6% increase in revenue from operations, totaling ₹7,215 crore.
Q3: What challenges did SRF face in its quarterly numbers?
Ans :- SRF experienced weaker-than-estimated quarterly numbers, primarily due to challenges in its chemicals business. Ebitda margin decreased to 18.5%, Ebitda was down by 32.1%, and net profit decreased by 50%.
Q4: How did Voltas perform in the December quarter?
Ans :- Voltas posted a net loss of ₹27.6 crore, narrowing from ₹110.5 crore a year ago. However, it achieved a healthy topline with a 31% YoY increase in consolidated revenue from operations, reaching ₹2,625.7 crore.
Q5: What strategic move did TCS announce today?
Ans :- TCS announced a 15-year expansion of its partnership with Aviva, the British insurance, wealth, and retirement provider. This move aims to transform Aviva's business and enhance customer experience.
Q6: What were the financial highlights for PB Fintech (Policybazaar's parent firm)?
Ans:- PB Fintech, the parent firm of Policybazaar, posted a net profit of ₹37 crore for the December quarter, a significant improvement from a net loss of ₹87 crore a year ago. Revenue from operations also saw a substantial 43% YoY jump, reaching ₹871 crore.
✅नवीनतम जानकारी के लिए, आपको वित्तीय न्यूज और वित्त सलाहकारों के साथ संपर्क करना चाहिए।
🔴💯ध्यान दें: ➡️ये सिर्फ कुछ उदाहरण हैं, और बाजार में कई और बेहतरीन ,Stocks,ईटीएफ उपलब्ध हैं. निवेश करने से पहले खुद का रिसर्च करना और फाइनेंशियल एडवाइजर से सलाह लेना जरूरी है.
🔴Disclaimer: This is not investment advice. Please conduct your own research before making any investment decisions.
Post a Comment